Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical rhenium-188 for Bowen's disease
IRCT20250921067313N2Phase 2Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rhenium in Bowen disease (BD), sponsored by Tehran University of Medical Sciences. Primary endpoint: Healing of Bowen's skin lesion. Started Oct 2026; status: recruiting.
02
Drugs
rhenium
03
Conditions
Bowen disease (BD)
Beyond the preview
Go deeper on IRCT20250921067313N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250921067313N2.